VivaBioCell Revenue and Competitors

VivaBioCell develops, manufactures and commercializes automated solutions for the manufacturing of advanced therapy medicinal products, for both research and clinical applications. The company, born as a university spin-off, has evolved over the years delivering several projects in the field of tissue engineering, medical devices and cell cultures automation, aimed at the development of new clinical applications. In 2015 VivaBioCell was acquired by ImmunityBio Inc. (formerly NantCell Inc.), a subsidiary of NantWorks LLC group (Culver City, California), an ecosystem of companies focused on biotech, healthcare AI, and mobility. This journey has brought into the company what we consider our main assets: the deep and diversified knowledge of our multidisciplinary team, together with strong and enduring partnerships with best-in-class clinical and technology stakeholders. Our mission is to provide smart and cost-effective solutions that allow for the improvement and standardization of advanced therapies manufacturing. Our systems together with the strong commitment in supporting the customers during all phases of set-up and validation, allow for a safe seamless conversion of a manual protocol into a high-standardized scalable process, drawing the attention on risk reduction and cost containment, while maintaining regulatory and quality requirements. Indeed, we truly want to inspire the application and diffusion of sustainable advanced therapies, with the long-term vision of bridging regenerative medicine into the mainstream worldwide clinical practice.